Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Wilms tumor 1 inhibitor

DRUG CLASS:

Wilms tumor 1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	galinpepimut-S Sensitive: B - Late Trials galinpepimut-S Sensitive : B	galinpepimut-S Sensitive: B - Late Trials galinpepimut-S Sensitive : B
WT1 expression	Malignant Pleural Mesothelioma	WT1 expression	Malignant Pleural Mesothelioma	nivolumab + galinpepimut-S Sensitive: C3 – Early Trials nivolumab + galinpepimut-S Sensitive : C3	nivolumab + galinpepimut-S Sensitive: C3 – Early Trials nivolumab + galinpepimut-S Sensitive : C3
WT1 expression	Ovarian Cancer	WT1 expression	Ovarian Cancer	pembrolizumab + galinpepimut-S Sensitive: C3 – Early Trials pembrolizumab + galinpepimut-S Sensitive : C3	pembrolizumab + galinpepimut-S Sensitive: C3 – Early Trials pembrolizumab + galinpepimut-S Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3